Press releases

ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement

ORYZON reports financial results and corporate update for quarter ended September 30, 2024

ORYZON announces formal grant of key European patent for vafidemstat

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress

ORYZON receives “Intention to grant” communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in first-line acute myeloid leukemia

ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications

ORYZON to provide corporate progress updates at several events in September

ORYZON reports financial results and corporate update for half-year ending June 30, 2024